Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Ten-year experience of the multidisciplinary Osteoncology Center.

Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T.

Support Care Cancer. 2019 Jan 16. doi: 10.1007/s00520-019-4635-5. [Epub ahead of print]

PMID:
30649614
2.

Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers.

Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T.

Dis Markers. 2018 Dec 2;2018:6878409. doi: 10.1155/2018/6878409. eCollection 2018.

3.

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age.

Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Endocr Connect. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478. [Epub ahead of print]

4.

Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line.

Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, Pieri F, Riva N, Bongiovanni A, Casadei R, Fausti V, Ibrahim T.

Cells. 2018 Oct 25;7(11). pii: E186. doi: 10.3390/cells7110186.

5.

Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers.

Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D.

J Vis Exp. 2018 Jun 11;(136). doi: 10.3791/57113.

PMID:
29939179
6.

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma.

De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T.

J Vis Exp. 2018 Apr 11;(134). doi: 10.3791/56767.

PMID:
29708525
7.

Myxofibrosarcoma primary cultures: molecular and pharmacological profile.

De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T.

Ther Adv Med Oncol. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28.

8.

Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.

De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T.

Int J Mol Sci. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662.

9.

Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.

Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Medicine (Baltimore). 2017 Nov;96(46):e8567. doi: 10.1097/MD.0000000000008567. Review.

10.

Primary leiomyosarcoma of the bone: a case report and a review of the literature.

Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T.

Medicine (Baltimore). 2017 Nov;96(45):e8545. doi: 10.1097/MD.0000000000008545. Review.

11.

Management and potentialities of primary cancer cultures in preclinical and translational studies.

Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

J Transl Med. 2017 Nov 7;15(1):229. doi: 10.1186/s12967-017-1328-z. Review.

12.

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines.

Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

J Vis Exp. 2017 Sep 13;(127). doi: 10.3791/56311.

PMID:
28930982
13.

Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.

Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, Bongiovanni A, Recine F, Amadori D, Ghetti M, Ibrahim T.

Int J Mol Sci. 2017 Jul 29;18(8). pii: E1655. doi: 10.3390/ijms18081655.

14.

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas.

Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017. Review.

15.

CORRECTION: Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):309. doi: 10.1242/bio.023911. No abstract available.

16.

Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway.

Amadori D, Serra P, Masalu N, Pangan A, Scarpi E, Bugingo AM, Katabalo D, Ibrahim T, Bongiovanni A, Miserocchi G, Spadazzi C, Liverani C, Turri V, Tedaldi R, Mercatali L.

Oncotarget. 2017 Feb 21;8(8):13142-13156. doi: 10.18632/oncotarget.14482.

17.

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT.

Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T.

Clin Lung Cancer. 2017 Jul;18(4):415-420. doi: 10.1016/j.cllc.2016.11.004. Epub 2016 Nov 21.

PMID:
27956089
18.

Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.

De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, Amadori D, Ibrahim T.

Molecules. 2016 Dec 3;21(12). pii: E1662.

19.

Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.

Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, Amadori D, Puisieux A, Rigaud M, Fabbri F.

Oncotarget. 2017 Jan 10;8(2):2423-2436. doi: 10.18632/oncotarget.13682.

20.

Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.

Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T.

Biol Open. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: Biol Open. 2017 Feb 15;6(2):309.

21.

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T.

Int J Mol Sci. 2016 Nov 1;17(11). pii: E1827.

22.

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T.

Onco Targets Ther. 2016 Oct 11;9:6233-6246. eCollection 2016. Review.

23.

RANKL: A promising circulating marker for bone metastasis response.

Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, Liverani C, De Vita A, La Manna F, Oboldi D, Serra P, Foca F, Cecconetto L, Amadori D, Mercatali L.

Oncol Lett. 2016 Oct;12(4):2970-2975. Epub 2016 Aug 8.

24.

[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.

Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D.

Int J Oncol. 2016 Sep;49(3):1260. doi: 10.3892/ijo.2016.3613. Epub 2016 Jul 6.

25.

Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).

Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.

Support Care Cancer. 2017 Jan;25(1):111-117. Epub 2016 Aug 27.

PMID:
27568305
26.

Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model.

Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E.

Int J Mol Sci. 2016 Aug 22;17(8). pii: E1375. doi: 10.3390/ijms17081375.

27.

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.

Bongiovanni A, Riva N, Ricci M, Mercatali L, Liverani C, La Manna F, De Vita A, Cavaliere D, Pieri F, Oboldi D, Verdecchia GM, Amadori D, Ibrahim T.

BMC Cancer. 2015 Dec 22;15:998. doi: 10.1186/s12885-015-2038-7.

28.

First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.

Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T.

Onco Targets Ther. 2015 Dec 3;8:3613-9. doi: 10.2147/OTT.S91971. eCollection 2015.

29.

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.

Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T.

Future Oncol. 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159.

PMID:
25525851
30.

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.

Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T.

Onco Targets Ther. 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014.

31.

Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report.

Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T.

Future Oncol. 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36.

PMID:
25303054
32.

ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling.

Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, Kang Y.

Nat Cell Biol. 2014 Oct;16(10):1004-15, 1-13. doi: 10.1038/ncb3040. Epub 2014 Sep 21.

33.

The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin.

Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim T, Amadori D, Kang Y.

J Biol Chem. 2014 Aug 8;289(32):21888-95. doi: 10.1074/jbc.M114.582866. Epub 2014 Jun 25.

34.

CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.

Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T.

Bone. 2014 Sep;66:214-22. doi: 10.1016/j.bone.2014.06.017. Epub 2014 Jun 20.

PMID:
24956020
35.

A new emergency in oncology: Bone metastases in breast cancer patients (Review).

Ibrahim T, Mercatali L, Amadori D.

Oncol Lett. 2013 Aug;6(2):306-310. Epub 2013 Jun 4.

36.

Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis.

Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y.

Cancer Cell. 2013 Oct 14;24(4):542-56. doi: 10.1016/j.ccr.2013.09.008.

37.

Bone and cancer: the osteoncology.

Ibrahim T, Mercatali L, Amadori D.

Clin Cases Miner Bone Metab. 2013 May;10(2):121-3. Review.

38.

What can we learn from the ZOOM trial?--Authors' reply.

Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T.

Lancet Oncol. 2013 Sep;14(10):e388-90. doi: 10.1016/S1470-2045(13)70295-X. No abstract available.

PMID:
23993381
39.

RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.

Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T.

Int J Mol Sci. 2013 May 23;14(6):10683-93. doi: 10.3390/ijms140610683.

40.

[Change in condylar and mandibular morphology in juvenile idiopathic arthritis: cone beam volumetric imaging].

Garagiola U, Mercatali L, Bellintani C, Fodor A, Farronato G, Lőrincz A.

Fogorv Sz. 2013 Mar;106(1):27-31. Hungarian.

PMID:
23650760
41.

Metastatic bone disease in the era of bone-targeted therapy: clinical impact.

Ibrahim T, Farolfi A, Mercatali L, Ricci M, Amadori D.

Tumori. 2013 Jan-Feb;99(1):1-9. doi: 10.1700/1248.13780. Review.

PMID:
23548992
42.

Multiple marker detection in peripheral blood for NSCLC diagnosis.

Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W.

PLoS One. 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401. Epub 2013 Feb 26.

43.

Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.

Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D.

Int J Oncol. 2013 Apr;42(4):1263-70. doi: 10.3892/ijo.2013.1809. Epub 2013 Feb 6. Erratum in: Int J Oncol. 2016 Sep;49(3):1260.

PMID:
23403907
44.

miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis.

Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF.

Nat Cell Biol. 2013 Mar;15(3):284-94. doi: 10.1038/ncb2690. Epub 2013 Feb 10.

45.

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.

Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D.

Oncology. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.

PMID:
23257904
46.

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D.

Cancer Cell Int. 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48.

47.

Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2.

Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukačišin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y.

Nat Cell Biol. 2012 Nov;14(11):1212-22. doi: 10.1038/ncb2607. Epub 2012 Oct 21.

48.

Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization.

Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y.

Nat Med. 2011 Aug 7;17(9):1101-8. doi: 10.1038/nm.2401.

49.

Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.

Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D.

Clin Breast Cancer. 2011 Dec;11(6):369-75. doi: 10.1016/j.clbc.2011.05.001. Epub 2011 Jul 20.

PMID:
21764390
50.

The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.

Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D.

Oncology. 2011;80(3-4):225-31. doi: 10.1159/000327585. Epub 2011 Jul 5.

PMID:
21734413

Supplemental Content

Loading ...
Support Center